Emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Drug Profile

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate

Alternative Names: Complera; Edurant/Truvada; Emtricitabine/tenofovir disoproxil fumarate/rilpivirine; Emtricitabine/tenofovir disoproxil fumarate/TMC 278; Eviplera; Rilpivirine/emtricitabine/tenofovir disoproxil fumarate; Rilpivirine/Truvada; Tenofovir disoproxil fumarate/rilpivirine/emtricitabine; Truvada/Edurant™; Truvada/TMC278

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen Pharmaceutical KK; Janssen R&D Ireland
  • Class Antiretrovirals; Deoxyribonucleosides; Nitriles; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides; Pyrimidines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 27 Feb 2017 Gilead Sciences has patent protection for emtricitabine/rilpivirine/tenofovir disoproxil fumarate ranolazine in USA and European Union (Gilead Sciences 10-k, February 2017)
  • 27 Aug 2015 Launched for HIV-1 infections in Japan (PO) before August 2015
  • 26 Jan 2015 Phase-III development is ongoing in Cameroon, Ghana, Kenya, Senegal, South Africa, Thailand and Uganda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top